A Clinical Trial to Evaluate the Effects of an Electrolyte Supplement on Women's Wellness

This study evaluates the effects of the Daily Love Electrolytes supplement on women's wellness over a 4-week period. The primary focus is on perceived hydration and energy levels, assessed via self-reported questionnaires at Baseline, Week 1, Week 2, Week 3, and Week 4. This is a single-arm, open-label, virtual trial enrolling 40 female participants aged 18 and older who have experienced low energy and feelings of dehydration in the past four weeks. All participants will take two electrolyte tablets daily as directed throughout the 4-week study duration.

Inclusion Criteria: * Be female * Be aged 18+ * Anyone experiencing issues regarding all of the following over the past four weeks: low energy and feeling dehydrated * Anyone who is generally healthy - does not live with any uncontrolled chronic disease * Willing to refrain from taking any products, prescription medications, or supplements that target energy, hydration, and general wellness during the test period * Willing to maintain a consistent level of water intake for the duration of the study * Willing to avoid other hydration products, including soluble products or pre-made beverages such as Pedialyte or Gatorlyte * Willing to maintain current diet, sleep schedule, and activity level for the duration of the study * Resides in the United States * Not currently partaking in another research study and will not be partaking in any other research study for the next 4 weeks and at any point during this study's duration Exclusion Criteria: * Anyone with pre-existing chronic conditions that would impact participation in the study, including cancer, mental health disorders, history of serious illness in the last three months, history of substance abuse, or planned surgery during the study period * Anyone with any allergies or sensitivities to any of the study product ingredients * Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period) * Anyone taking prescription Eskalith or Lithobid (lithium) * Anyone taking prescription Lanoxin (digoxin) * Anyone diagnosed with and is being treated for Parkinson's Disease with prescription medications * Anyone taking prescription antibiotics in the study duration * Anyone diagnosed with kidney disease * Anyone unwilling to follow the study protocol